Robert Schwartz

Medawar Prize Laureate (2000)

1928-2017

Making Transplants a Reality:
Robert S. Schwartz figured out how to prevent organ rejection


More than 700,000 people in the United States received organ transplants over the past three decades—an incredible number considering that just 60 years ago, it was virtually impossible to transplant tissue without it being violently, and usually fatally, rejected by a patient’s body. (The only successful transplants up to that point had been between identical twins.) It wasn’t until 1958 that Tufts professor and hematologist Robert S. Schwartz made them feasible by uncovering a medical means for suppressing the human immune response.

Read More

It started one morning in 1957 during ward rounds at New England Medical Center. Three leukemia patients had died after undergoing total body irradiation to prepare them for accepting transplants of healthy bone marrow. That morning, William Dameshek, the chief of hematology at Tufts, lectured his department—including Schwartz—about the risks of total body irradiation, which at the time was the only existing option for tamping down the immune system. “He said that we need another way,” Schwartz later recalled. “He assigned the task of finding it to me.”

Schwartz and Dameshek noted that under a microscope, the immune response involves a proliferation of cells—one that bears a striking resemblance to leukemia—and wondered whether it might be possible to chemically suppress it. Schwartz then contacted two pharmaceutical companies for samples of antileukemic drugs to test on rabbits. The first drug he administered, 6-mercaptopurine, suppressed the animals’ immune response, and Schwartz recalled “dancing in the lab” with a research fellow when they saw the evidence.

Schwartz and Dameshek then co-wrote a series of papers in 1958 and 1959 definitively showing that using 6-mercaptopurine to temporarily shut off the immune system response at the time of transplantation could stop organ rejection. Their research quickly spawned other studies, with researchers in the U.S. and England using the drug to successfully transplant skin and kidneys in dogs and other animals.

“It’s unusual to see a discovery have so much impact, to see a breakthrough change practice so profoundly for the better,” said John K. Erban, M81, a professor at Tufts University School of Medicine and the clinical director of Tufts Cancer Center. In 1962, doctors performed the first human kidney transplant using a deceased donor, and the first liver transplant followed a year later. In 1967, a heart transplant was successful.

In 2000, the Transplantation Society awarded Schwartz its Medawar Prize, the field’s highest honor, and his outsized contributions to transplantation were also mentioned in two Nobel Prize speeches. And Schwartz didn’t stop at transplantation: In the 1960s, he applied his chemical immunosuppression knowledge to fight autoimmune disorders. Schwartz died last August, but the lessons learned from his research will live on in the treatment of cancer and other diseases.

Genevieve Rajewski, Tufts Magazine

The Medawar Prize - 2000


Robert Schwartz was awarded the Medawar Prize for his pioneering work in the development of organ transplantation and the treatment of autoimmune diseases by suppressing the immune system.

Highlighted Articles


Robert S. Schwartz, MD: The Dawn of Immunosuppression

Robert S. Schwartz
Transplantation: November 2015 - Volume 99 - Issue 11 - p 2239-2240 doi: 10.1097/TP.0000000000000987

Transplantation: What event or individual led you into the field of immunology?

RS: In 1956, I was a 28-year-old medical resident at the Yale-New Haven Medical Center. Like many of my peers, my plans for the future were vague. I had published 2 case reports, 1 about an electrocardiographic phenomenon called electrical alternans; the other, about a case of leukopenia, which turned me towards hematology, but I wasn't ready to make a commitment. In any case, I didn't know how to proceed after my residency.

Drug Induced Immunological Tolerance and Transplantation

Robert S. Schwartz
Transplantation: July 1967 - Volume 5 - Issue 4 - p 1215-1216

Immunosuppression as applied to transplantation has as its principal goal the permanent deletion of immunologic reactivity against a given set or antigens. This aim has already been partially achieved in laboratory animals. The major task remaining is the application of these experimental findings to a clinically realistic solution ol the problem ol transplantation in man.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada